摘要
目的研究达美康(格列齐特)联合短效胰岛素腹腔给药在糖尿病肾病腹膜透析患者中的应用综合分析。方法将2001~2013年3月在我院接受腹膜透析治疗的66例终末期糖尿病肾病患者纳入研究,随机分为观察组给予达美康(格列齐特)联合腹腔内用短效胰岛素治疗终末期糖尿病肾病和对照组给予胰岛素腹腔内用降糖治疗。治疗后12w时,比较两组患者的血糖水平、胰岛素用量、肾功能情况以及不良反应例数。结果①治疗后12w时,观察组患者的空腹血糖、餐后血糖、糖化血红蛋白含量、单日胰岛素用量水平均低于对照组,血糖控制达标率高于对照组;②治疗12w内,观察组患者发生腹膜炎、心血管事件、低血糖反应、死亡的例数少于对照组。结论达美康(格列齐特)联合短效胰岛素腹腔用药降糖治疗有助于控制血糖水平、降低胰岛素用量、改善肾功能、减少不良反应发生率,是终末期糖尿病肾病腹膜透析患者理想的降糖方案。
Objective To observe the application value and Comprehensive analysis combined with short-acting insulin therapy in diabetic nephropathy patients received peritoneal dialysis.Methods 66 cases of diabetic nephropathy patients who received peritoneal dialysis in our hospital from 2001 to 2013.3 were enrol ed and randomly divided into observation group given Diamicron combined with short-acting insulin and control group only given insulin.After 12 weeks of treatment,blood glucose levels,insulin dosage,renal function and cases of adverse reactions were observed.Results①After 12weeks treatment,fasting blood glucose,postprandial blood glucose,glycated hemoglobin content,daily insulin dosage levels of observation group were lower than those of control group,blood glucose control compliance rate was higher than control group;②During 12 weeks treatment,cases of peritonitis,hypoglycemia,cardiovascular events,death of observation group were less than those of control group.Conclusion Diamicron combined with short-acting insulin are ideal hypoglycemic therapy in end-stage diabetic nephropathy received peritoneal dialysis for it is helpful to control blood glucose levels,reduce the dosage of insulin,improve kidney function,and to reduce the incidence of adverse events.
作者
李绍强
谭光长
杨志鹏
梁伟华
邱科
陈样过
LI Shao-qiang;TAN Guang-chang;YANG Zhi-peng;LIANG Wei-hua;QIU Ke;CHEN Xiang-guo(Jiangmen City Second People'Hospital of Xinhui District,Jiangmen 529100,Guangdong,China)
关键词
糖尿病肾病
腹膜透析
达美康
胰岛素
不良反应
Diabetic nephropathy
Peritoneal dialysis
Diamicron
insulin
Adverse event
